NewBioRx produces BPC-157 using controlled solid-phase peptide synthesis (SPPS), followed by purification through high-performance liquid chromatography (HPLC) to remove truncated peptide fragments and synthesis byproducts
Journal of Orthopaedic Research , 21(6), 976-983
Heier I, Syland E, Krogstad AL, et al
Impurities that rarely matter in adult regenerative protocols but introduce additional variables when fetal development is at stake
I've done both of them
The FDAs Stance and Why It Misses the Mark In 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance , meaning it raises significant safety concerns. The agency specifically cited risks of immunogenicity , peptide-related impurities , and lack of sufficient safety data for human use